Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% During the Study Period (2020-2034) | DelveInsight
The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among ...
Merkel Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...
Watch out for these signs of skin cancer, experts say
It can be alarming to see a new spot appear on your skin, especially if it's rapidly growing. Here's what experts need you to ...
Physician's Weekly6d
Immune Checkpoint Inhibitors and Survival Trends in MCC
The following is a summary of “Improved survival at the population level for patients with advanced Merkel cell carcinoma ...
BioWorld11d
AURKB unveiled as a druggable target in Merkel cell carcinoma
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality rate and characterized by ...
Managed Healthcare Executive7d
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...
Local veterans fear future amid 80,000 Department of Veterans Affairs job cuts
Earlier this week, the Trump Administration announced plans to eliminate 80,000 jobs nationwide within the Department of ...
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
"We are excited with the rapid completion of enrollment of the third safety cohort," said Robert Bitterman, CEO of Phio Pharmaceuticals. "We look forward to rapidly advancing the study to bring an ...